Trials / Terminated
TerminatedNCT00836927
Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016, NCT00112372; and MK-8669-028, NCT00704054) with deforolimus and/or in those who remain in long-term follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ridaforolimus Tablet | Ridaforolimus 10 mg oral tablet |
| DRUG | Ridaforolimus Intravenous (IV) Infusion | Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle). |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2017-04-03
- Completion
- 2018-02-04
- First posted
- 2009-02-04
- Last updated
- 2019-02-18
- Results posted
- 2018-05-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00836927. Inclusion in this directory is not an endorsement.